BRPI0510269A - composições de dalbavancina para o tratamento de infecções bacterianas - Google Patents
composições de dalbavancina para o tratamento de infecções bacterianasInfo
- Publication number
- BRPI0510269A BRPI0510269A BRPI0510269-3A BRPI0510269A BRPI0510269A BR PI0510269 A BRPI0510269 A BR PI0510269A BR PI0510269 A BRPI0510269 A BR PI0510269A BR PI0510269 A BRPI0510269 A BR PI0510269A
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- dalbavancin
- bacterial infections
- compositions
- infection
- Prior art date
Links
- 208000035143 Bacterial infection Diseases 0.000 title abstract 5
- 208000022362 bacterial infectious disease Diseases 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 5
- 229960002488 dalbavancin Drugs 0.000 title abstract 4
- 108700009376 dalbavancin Proteins 0.000 title abstract 4
- KGPGQDLTDHGEGT-JCIKCJKQSA-N zeven Chemical compound C=1C([C@@H]2C(=O)N[C@H](C(N[C@H](C3=CC(O)=C4)C(=O)NCCCN(C)C)=O)[C@H](O)C5=CC=C(C(=C5)Cl)OC=5C=C6C=C(C=5O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@H](O5)C(O)=O)NC(=O)CCCCCCCCC(C)C)OC5=CC=C(C=C5)C[C@@H]5C(=O)N[C@H](C(N[C@H]6C(=O)N2)=O)C=2C(Cl)=C(O)C=C(C=2)OC=2C(O)=CC=C(C=2)[C@H](C(N5)=O)NC)=CC=C(O)C=1C3=C4O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O KGPGQDLTDHGEGT-JCIKCJKQSA-N 0.000 title abstract 4
- 238000000034 method Methods 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 210000004872 soft tissue Anatomy 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
- C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
COMPOSIçõES DE DALBAVANCINA PARA O TRATAMENTO DE INFECçõES BACTERIANAS A invenção proporciona métodos e composições para o tratamento de infecções bacterianas. A composição pode ser uma combinação de fatores, os quais incluem A~ 0~, A~ 1~, B~ 1~, B~ 2~, C~ 0~, C~ 1~, isoB~ 0~, e MAG, na presença de solvente em baixo nível. Os métodos da invenção incluem a administração de formulações de dalbavancina para o tratamento de uma infecção bacteriana, em particular uma infecção por bactérias Gram-positivas da pele e do tecido mole, Os regimes de dosagem incluem a administração de doses múltiplas de dalbavancina, a qual freqüentemente permanece em níveis terapêuticos na corrente sanguínea por pelo menos uma semana, proporcionando ação terapêutica prolongada contra una infecção bacteriana. Os regimes de dosagem para pacientes renais estão também incluídos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/834.395 | 2004-04-27 | ||
| US10/834,395 US7119061B2 (en) | 2002-11-18 | 2004-04-27 | Dalbavancin compositions for treatment of bacterial infections |
| PCT/US2005/014355 WO2006078277A2 (en) | 2004-04-27 | 2005-04-26 | Dalbavancin compositions for treatment of bacterial infections |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0510269A true BRPI0510269A (pt) | 2007-10-30 |
| BRPI0510269B1 BRPI0510269B1 (pt) | 2019-08-06 |
| BRPI0510269B8 BRPI0510269B8 (pt) | 2021-05-25 |
Family
ID=36692659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0510269A BRPI0510269B8 (pt) | 2004-04-27 | 2005-04-26 | composições de dalbavancina para o tratamento de infecções bacterianas |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US7119061B2 (pt) |
| EP (1) | EP1748786A4 (pt) |
| JP (2) | JP5207734B2 (pt) |
| KR (2) | KR20070015179A (pt) |
| CN (1) | CN1964736B (pt) |
| AU (2) | AU2005325261B2 (pt) |
| BR (1) | BRPI0510269B8 (pt) |
| CA (1) | CA2564112C (pt) |
| IL (1) | IL178207A (pt) |
| MX (1) | MXPA06012301A (pt) |
| NO (1) | NO345529B1 (pt) |
| NZ (2) | NZ588109A (pt) |
| RU (2) | RU2352353C2 (pt) |
| SG (1) | SG152274A1 (pt) |
| WO (1) | WO2006078277A2 (pt) |
| ZA (2) | ZA200607889B (pt) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7119061B2 (en) | 2002-11-18 | 2006-10-10 | Vicuron Pharmaceuticals, Inc. | Dalbavancin compositions for treatment of bacterial infections |
| US20060074014A1 (en) * | 2002-11-18 | 2006-04-06 | Vicuron Pharmaceuticals Inc. | Dalbavancin compositions for treatment of bacterial infections |
| MXPA05005338A (es) * | 2002-11-18 | 2005-12-14 | Vicuron Pharm Inc | Metodos para administrar dalbavancin para el tratamiento de infecciones bacterianas. |
| KR102083046B1 (ko) | 2012-06-07 | 2020-02-28 | 칠드런＇스 하스피틀 로스 앤젤레스 | 레티노이드 작용제를 이용하여 호중구감소증을 치료하기 위한 방법 |
| CN103087918B (zh) * | 2013-02-20 | 2015-04-22 | 广州市微生物研究所 | 一种好氧反硝化菌剂及其制备与应用 |
| KR102237887B1 (ko) | 2013-03-15 | 2021-04-07 | 멜린타 서브시디어리 코프. | 항생제를 사용하여 과체중 및 비만 환자에서 감염을 치료하는 방법 |
| MX2016010699A (es) | 2014-02-18 | 2017-10-11 | Children's Hospital Los Angeles | Composiciones y metodos para tratar neutropenia. |
| EP3169345B1 (en) | 2014-07-17 | 2025-01-29 | Melinta Therapeutics, LLC | High purity oritavancin and method of producing same |
| US20200171124A1 (en) | 2016-04-15 | 2020-06-04 | Lupin Limited | Topical compositions for ophthalmic and otic use |
| KR20190005940A (ko) * | 2016-05-09 | 2019-01-16 | 셀리아 파마슈티칼즈 에이피에스 | 안정화된 글리코펩티드 항생제 제형 |
| RU2019119405A (ru) * | 2016-11-23 | 2020-12-25 | Гуфик Байосайенсиз Лимитед | Лиофилизированные фармацевтические композиции далбаванцина |
| CN109946398B (zh) * | 2019-03-28 | 2022-05-24 | 丽珠集团新北江制药股份有限公司 | 一种检测达巴万星及其杂质的方法 |
| US20230218644A1 (en) | 2020-04-16 | 2023-07-13 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
| CN113666987A (zh) * | 2020-05-14 | 2021-11-19 | 博瑞生物医药泰兴市有限公司 | 一种达巴万星的纯化方法 |
| CN111686240B (zh) * | 2020-06-14 | 2021-04-09 | 中国科学院昆明动物研究所 | 达巴万星在制备抑制SARS-CoV-2与ACE2结合的药物中的应用 |
| CN115219626A (zh) * | 2022-07-18 | 2022-10-21 | 丽珠集团福州福兴医药有限公司 | 达巴万星合成反应的分析方法 |
| AU2023359653A1 (en) * | 2022-10-12 | 2025-05-29 | Hikma Pharmaceuticals Usa Inc. | Liquid dalbavancin composition |
| CN116355056A (zh) * | 2023-05-12 | 2023-06-30 | 丽珠集团福州福兴医药有限公司 | 一种适合大规模生产的达巴万星制备方法 |
| WO2025158262A1 (en) | 2024-01-23 | 2025-07-31 | Lupin Limited | Stable pharmaceutical compositions of dalbavancin as ready-to-dilute formulation |
| GB202405997D0 (en) | 2024-04-29 | 2024-06-12 | Arecor Ltd | Novel compositions |
| GB202405996D0 (en) | 2024-04-29 | 2024-06-12 | Arecor Ltd | Novel compositions |
| CN119157832B (zh) * | 2024-07-26 | 2025-09-12 | 健进制药有限公司 | 丙二醇的水溶液在抑制盐酸达巴万星降解中的应用、达巴万星注射液制剂、制备方法及应用 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1496386A (en) | 1975-03-05 | 1977-12-30 | Lepetit Spa | Antibiotics |
| US4195079A (en) | 1979-01-31 | 1980-03-25 | Pfizer Inc. | New polycyclic ether antibiotic |
| CA1183789A (en) | 1981-08-04 | 1985-03-12 | Kiyoshi Isono | Antibiotic 76-11, process for the production thereof, anticoccidiosis agent and domestic animals growth accelerator comprising the same as an effective ingredient |
| US4578271A (en) | 1982-05-24 | 1986-03-25 | Fujisawa Pharmaceutical Co., Ltd. | Biologically active WS 6049 substances, a process for the production thereof and their pharmaceutical compositions |
| FI73697C (fi) | 1982-06-08 | 1987-11-09 | Lepetit Spa | Foerfarande foer framstaellning av individuella faktorer 1, 2, 3, 4 och 5 av teikomysin a2. |
| FR2548021B1 (fr) | 1983-06-29 | 1986-02-28 | Dick P R | Compositions pharmaceutiques dermiques a action prolongee et continue a base d'acides gras essentiels |
| GB8415092D0 (en) | 1984-06-13 | 1984-07-18 | Lepetit Spa | Ester derivatives |
| GB8425685D0 (en) | 1984-10-11 | 1984-11-14 | Lepetit Spa | Antibiotic a 40926 complex |
| GB8428619D0 (en) | 1984-11-13 | 1984-12-19 | Lepetit Spa | Derivatives of antibiotic l 17046 |
| US4914187A (en) | 1984-11-13 | 1990-04-03 | Gruppo Lepetit S.P.A | Ester derivatives of antibiotic L 17046 |
| GB8512795D0 (en) | 1985-05-21 | 1985-06-26 | Lepetit Spa | Increasing ratio of components of teicoplanin a2 complex |
| GB8531846D0 (en) | 1985-12-30 | 1986-02-05 | Lepetit Spa | Antibiotic a 40926 mannosyl aglycon |
| GB8608809D0 (en) | 1986-04-11 | 1986-05-14 | Lepetit Spa | Antibiotic |
| GB8621911D0 (en) | 1986-09-11 | 1986-10-15 | Lepetit Spa | Increasing ratio of components of anti-biotic complex |
| GB8621912D0 (en) | 1986-09-11 | 1986-10-15 | Lepetit Spa | Increasing ratio of components of anti-biotic complex |
| GR871488B (en) | 1986-10-10 | 1987-11-12 | Lepetit Spa | New antibiotics |
| GB8715735D0 (en) | 1987-07-03 | 1987-08-12 | Lepetit Spa | De-mannosyl teicoplanin derivatives |
| US4882313A (en) | 1987-07-31 | 1989-11-21 | Smithkline Beckman Corporation | Carboxamide derivatives of glycopeptides |
| GB8726859D0 (en) | 1987-11-17 | 1987-12-23 | Lepetit Spa | 22-dechlorotei-coplanins |
| EP0376041B1 (en) | 1988-12-27 | 1996-02-28 | GRUPPO LEPETIT S.p.A. | C63-Amide derivatives of 34-de(acetylglucosaminyl)-34-deoxy-teicoplanins |
| IE64155B1 (en) | 1989-03-29 | 1995-07-12 | Lepetit Spa | New substituted alkylamide derivatives of teicoplanin |
| JPH03193735A (ja) * | 1989-12-22 | 1991-08-23 | Shionogi & Co Ltd | グリコペプチド系抗生物質の安定化組成物 |
| US5030619A (en) | 1990-04-16 | 1991-07-09 | Miles Inc. | Synergistic fungicidal composition |
| US5606036A (en) | 1991-03-27 | 1997-02-25 | Gruppo Lepetit Spa | Antibiotic A 40926 ester derivatives |
| EP0596929B1 (en) * | 1991-07-29 | 1995-07-26 | GRUPPO LEPETIT S.p.A. | Amide derivatives of antibiotic a 40926 |
| US5750509A (en) | 1991-07-29 | 1998-05-12 | Gruppo Lepetit S.P.A. | Amide derivatives of antibiotic A 40926 |
| US6384013B1 (en) | 1992-03-19 | 2002-05-07 | Eli Lilly And Company | Cyclic peptide antifungal agents and process for preparation thereof |
| US5882900A (en) | 1992-09-10 | 1999-03-16 | Gruppo Lepetit S.P.A. | Process for the selective increase of production of antibiotic GE 2270 factor a by adding vitamin B12 to nutrient medium |
| CN1036654C (zh) * | 1993-01-01 | 1997-12-10 | 格鲁波莱佩蒂特公司 | 抗菌素a40926的酰氨衍生物及其制备方法 |
| WO1996024608A1 (en) | 1995-02-07 | 1996-08-15 | Biosearch Italia S.P.A. | Basic oxazoline-amide derivatives of ge 2270 and ge 2270-like antibiotics |
| DE69600244T2 (de) | 1995-02-07 | 1998-10-01 | Biosearch Italia Spa | Basische prolinamid derivate von ge2270 und ge2270-ahnlichten antibiotika |
| ES2186866T3 (es) | 1996-02-14 | 2003-05-16 | Biosearch Italia Spa | Derivados de factores del antibiotico ge2270. |
| AU2441697A (en) | 1996-04-12 | 1997-11-07 | Eli Lilly And Company | Covalently-linked glycopeptide dimers |
| EP0912604B1 (en) | 1996-04-23 | 2001-11-14 | Biosearch Italia S.p.A. | Improved chemical process for preparing amide derivatives of antibiotic A 40926 |
| US5935238A (en) | 1997-06-19 | 1999-08-10 | Sun Microsystems, Inc. | Selection from multiple fetch addresses generated concurrently including predicted and actual target by control-flow instructions in current and previous instruction bundles |
| CA2255140A1 (en) | 1997-12-23 | 1999-06-23 | Eli Lilly And Company | Echinocandin binding domain of 1,3-.beta.-glucan synthase |
| US6417180B1 (en) * | 1998-10-07 | 2002-07-09 | University Of Massachusetts | Zinc finger-reactive antimicrobial compounds |
| TWI233805B (en) * | 1999-07-01 | 2005-06-11 | Fujisawa Pharmaceutical Co | Stabilized pharmaceutical composition in lyophilized form as antifungal agent |
| JP4931282B2 (ja) * | 2000-10-02 | 2012-05-16 | 日本ケミカルリサーチ株式会社 | 生理活性ペプチド含有粉末 |
| EP1343518B1 (en) * | 2000-11-07 | 2009-07-22 | Novartis Vaccines and Diagnostics, Inc. | Stabilized interferon compositions |
| US7119061B2 (en) | 2002-11-18 | 2006-10-10 | Vicuron Pharmaceuticals, Inc. | Dalbavancin compositions for treatment of bacterial infections |
| MXPA05005338A (es) | 2002-11-18 | 2005-12-14 | Vicuron Pharm Inc | Metodos para administrar dalbavancin para el tratamiento de infecciones bacterianas. |
-
2004
- 2004-04-27 US US10/834,395 patent/US7119061B2/en not_active Expired - Lifetime
- 2004-06-02 US US10/860,723 patent/US20050004051A1/en not_active Abandoned
-
2005
- 2005-04-26 CN CN2005800185632A patent/CN1964736B/zh not_active Expired - Lifetime
- 2005-04-26 MX MXPA06012301A patent/MXPA06012301A/es active IP Right Grant
- 2005-04-26 JP JP2007510906A patent/JP5207734B2/ja not_active Expired - Lifetime
- 2005-04-26 NZ NZ588109A patent/NZ588109A/en not_active IP Right Cessation
- 2005-04-26 KR KR1020067022355A patent/KR20070015179A/ko not_active Ceased
- 2005-04-26 EP EP05856652A patent/EP1748786A4/en not_active Ceased
- 2005-04-26 NO NO20064287A patent/NO345529B1/no unknown
- 2005-04-26 BR BRPI0510269A patent/BRPI0510269B8/pt active IP Right Grant
- 2005-04-26 CA CA2564112A patent/CA2564112C/en not_active Expired - Lifetime
- 2005-04-26 KR KR1020087011850A patent/KR100930982B1/ko not_active Expired - Lifetime
- 2005-04-26 RU RU2006136736/15A patent/RU2352353C2/ru active
- 2005-04-26 AU AU2005325261A patent/AU2005325261B2/en not_active Expired
- 2005-04-26 SG SG200902872-1A patent/SG152274A1/en unknown
- 2005-04-26 WO PCT/US2005/014355 patent/WO2006078277A2/en not_active Ceased
- 2005-04-26 NZ NZ550053A patent/NZ550053A/en not_active IP Right Cessation
-
2006
- 2006-09-20 IL IL178207A patent/IL178207A/en active IP Right Grant
- 2006-09-20 ZA ZA200607889A patent/ZA200607889B/xx unknown
- 2006-09-20 ZA ZA200607888A patent/ZA200607888B/en unknown
-
2008
- 2008-10-30 RU RU2008142899/15A patent/RU2008142899A/ru not_active Application Discontinuation
-
2011
- 2011-02-01 AU AU2011200423A patent/AU2011200423B2/en not_active Expired
-
2012
- 2012-09-24 JP JP2012209510A patent/JP2013014613A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0510269A (pt) | composições de dalbavancina para o tratamento de infecções bacterianas | |
| MXPA05005338A (es) | Metodos para administrar dalbavancin para el tratamiento de infecciones bacterianas. | |
| CY1116215T1 (el) | Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης | |
| CU23423B7 (es) | Oxazolidinonas sustituidas y su uso en el campo de la coagulación sanguínea | |
| Zhadan et al. | Surgical site irrigation in plastic surgery | |
| BRPI0406667A (pt) | Método para o tratamento de câncer, e, formulação terapeuticamente aceitável de 2-dg | |
| BR0000003A (pt) | Azalidas e métodos de preparação das mesmas | |
| AR082803A1 (es) | Metodos y formulaciones para el tratamiento de la trombosis con betrixaban y un inhibidor de la glicoproteina p | |
| MX2024010591A (es) | Compuestos y metodos para el tratamiento de infecciones virales. | |
| WO2005089738A3 (en) | Use and administration of bacterial efflux pump inhibitors | |
| BR0315573A (pt) | Método para tratar, prevenir, controlar e/ou modificar dor em um paciente e composição farmacêutica | |
| ATE528311T1 (de) | Glycomimetische inhibitoren des pa-il-lectins, pa-iil-lectins oder beider lectine aus pseudomonas | |
| AR048324A1 (es) | Metodos para tratar infecciones por vih | |
| EA200501821A1 (ru) | Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат | |
| BR0110382A (pt) | Utilização de composições antibióticas azalida para o tratamento ou prevenção de uma infecção causada por bactérias ou protozoários em mamìferos | |
| Poeppl et al. | Daptomycin, fosfomycin, or both for treatment of methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model | |
| BR112021018815A2 (pt) | Gepotidacina para uso no tratamento de infecções bacterianas do trato urinário | |
| Eskandarinezhad et al. | The comparison of calcium hydroxide, curcumin, and Aloe vera antibacterial effects on 6-week-old Enterococcus faecalis biofilm as an intracanal medicament: An: in vitro: study | |
| CL2024001520A1 (es) | Nueva composición farmacéutica oral y régimen de dosificación para la terapia de enfermedades pulmonares intersticiales | |
| MX2009003912A (es) | Metodos y composiciones usando compuestos inmunomoduladores para el tratamiento y manejo de enfermedades bacterianas por espiroquetas y otras bacterias intracelulares obligadas. | |
| Scheinfeld | Extensive hidradenitis suppurativa (HS) Hurly stage III disease treated with intravenous (IV) linezolid and meropenem with rapid remission | |
| BRPI0414518A (pt) | composições farmacêuticas e métodos compreendendo combinações de derivados de 2-alquilideno-19-nor-vitamina d e hormÈnio paratireoidiano | |
| MX2008008556A (es) | Derivados de triterpenoquinonas y triterpenofenoles y su aplicacion para el tratamiento de tumores y enfermedades parasitarias. | |
| BR0309878A (pt) | Heterotriciclil-6-alquilideno-penemas como inibidores de beta-lactamase | |
| AR057876A1 (es) | Tratamiento de pacientes con enfermedad renal cronica (erc) utilizando compuestos de la invencion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: PAGAR RESTAURACAO. |
|
| B08H | Application fees: decision cancelled [chapter 8.8 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 NA RPI 2260 DE 29/04/2014 |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/08/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/08/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/04/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |